Investigating the HIV Infected Reservoir to Find a Cure
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
This study is trying to find ways to cure HIV by looking at the hidden virus in the blood of different groups of people living with HIV.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | cART |
| Locations | 1 site (Rotterdam) |
| Trial ID | NCT05215704 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize and target the latent HIV infected reservoir in patients to explore potential strategies for curing HIV. It involves collecting peripheral blood mononuclear cells and whole blood from HIV-infected individuals to assess the impact of latency disruptors on the reservoir. The study will include various patient groups, such as those with HIV-1 and HIV-2 infections, long-term non-progressors, elite controllers, and post-treatment controllers. Participants may also consent to longitudinal follow-up for up to four years to gather additional data.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with confirmed HIV-1 or HIV-2 infections.
Not a fit: Patients with major comorbidities or those unable to undergo necessary blood sampling may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to effective strategies for eradicating HIV from the body.
How similar studies have performed: Other studies have explored similar approaches to targeting the HIV reservoir, but this specific methodology is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 years or older. 2. Confirmed HIV-1 or HIV-2 infection. Exclusion Criteria: 1. Inability to place 2.5 cm venous catheter or perform phlebotomy 2. Major comorbidities: A. Severe symptomatic anemia B. Recent symptomatic cardiovascular event (unstable angina pectoris, decompensated heart failure, myocardial infarction). 3. The inability to participate due to any other relevant medical, social, environmental, psychological, factors or according to the HIV treating physician's judgement
Where this trial is running
Rotterdam
- Erasmus Medical Centre — Rotterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Casper Rokx, MD PhD — Erasmus Medical Center
- Study coordinator: Casper Rokx, MD PhD
- Email: c.rokx@erasmusmc.nl
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.